Valuation Methods for Child Healthcare
Assessing the value of healthcare interventions for children is made difficult by the lack of solid measures for metrics like quality of life. In a new article in Value & Health Outcomes Spotlight, Christiane Truelove discusses the difficulties in value-assessment for child healthcare and explores options for moving forward.
Improving Access to Cancer Therapeutics Through Value-based Care
Qatar provides free cancer care, greatly improving health outcomes at a substantial cost. A newly published pre-print paper in BMC Health Sciences Research examines and puts forward value-based care strategies for cancer care and value-assessment models to help reduce the financial burden of oncology care without sacrificing patient access to life-saving drugs.
Lecanemab May Avoid Aduhelm’s Fate With CMS
New data from Eisei suggests that its Alzheimer's drug lecanemab may not share the same fate as aduhelm, which was pulled from the market after the Centers for Medicare and Medicaid Services (CMS) agreed to only reimburse the drug for patients in randomized clinical trials. The results show that the drug was able to slow cognitive decline by 27% over 18 months, which may meet the agency’s requirements. However, Eisei is being cautious with its pricing.
Pedometer-Based Web Intervention for COPD Yields Big Savings
A new article in the AJMC investigated the cost-benefits of a web-based intervention for chronic obstructive pulmonary disease (COPD). The intervention used a pedometer linked to a web app to track the physical activity of COPD patients and encourage them in the process. An economic evaluation of the intervention over 12 months showed substantial savings in health care costs.
Value in Health Regional Issues: Developing Population-Based Valuation Techniques to Improve Health Equity in Uganda
Using insights from health economics and outcomes research (HEOR) to reduce health disparities requires assessing the population’s views, preferences, and aversions regarding health inequity. A recently published paper in Value in Health: Regional Issues found that surveys assessing these views in higher-income countries are effective in Uganda, meaning they can be applied to lower- and middle-income nations.
BioMarin’s Gene Therapy Roctavian More Cost-Effective in Hemophilia A than Genentech and Chugai’s Hemlibra
ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts that the one-time price of $2.5 million for Roctavian will be substantially lower than that of 12 years worth of Hemlibra at $640,000 annually.
Lyfegen Nets $8 Million in Funding Deal to Support Value-Based Healthcare
The healthtech company Lyfegen has received $8 million in a Series A financing round to support its value-based pricing platform. With the cost of new biologics rising and the industry pivoting to value-based pricing, payer organizations need solutions to negotiate reimbursement. Lyfegen’s platform consolidates the process from start to finish. The funding will help the company expand these offerings for clients.
Making Next-Gen Sequencing Accessible to Patients
Next-generation sequencing (NGS) is essential for advances in individualized medicine, but getting it to patients requires convincing insurers to pay for the technique. For this goal, care must be taken to ensure an accurate value-assessment process. In a new article in Value and Outcomes Spotlight, Lieven J.P. Annemans, PhD, discusses the barriers patients face accessing NGS and proposes a plan of action to reduce them.
Becker’s Healthcare – 13th Annual Meeting – April 2023
Beckers’ Healthcare is hosting its 13th annual meeting in April 2023. The conference will bring together professionals from across the healthcare industry to network and collaborate solutions for the rapidly changing healthcare landscape. Speakers include industry leaders, celebrities, investors, and more.
ICER Review Casts Doubt on Value of Two ALS Drug Candidates
A new report by the Institute for Clinical and Economic Review (ICER) finds that 2 amytrophic lateral sclerosis (ALS) drug candidates from Amylyx and Mitsubishi Tanabe Pharma America have “low long-term value at their current suggested prices. Although the drugs both provide some benefits over the standard of care, the benefits do not justify the high price tag, the report notes.
Cytel Webinar: US Drug Pricing Reform: Potential impact on Pharma HEOR Evidence Generation – September 8th
The new drug pricing legislation passed by the US government is set to change the game for the pharmaceutical industry. Medicare will negotiate the prices of certain drugs, so making a convincing case for a drug’s value is more important than ever. In a new Cytel webinar on September 8th, Cytel’s Anna Forsythe and Dr. Edmund Pezalla of Enlightenment Bioconsult will discuss the effects of the new legislation on drug pricing and how to use health economics and outcomes research (HEOR) in value assessment.
New Value in Health Article: Limitations of Conventional Cost-Effectiveness Analysis and the ISPOR Value Flower
Conventional methods of cost-effectiveness often overlook key value elements for patients. The “ISPOR Value Flower,” introduced in the 2018 ISPOR [...]
Evidence Generation for Patient-Centered Health Technology Assessment
Health technology assessments are increasingly shifting from payer-focused analyses towards a more patient-centered approach. However, understanding what value metrics patients [...]
ISPOR 2022 – Paying for Digital Therapeutics (DTx): What Evidence Is Needed?
There is currently no consensus between stakeholders on the value of DTx, or software-based approaches to treatment or prevention of [...]
Bringing Patient Voices into Health Technology Assessment
In a new Frontiers in Medical Technology perspective, authors Janet L. Wale and colleagues make the case that patient input [...]
ICER Publishes Cost-Effectiveness Study of Remdesivir for COVID-19 Patients
Researchers from the Institute for Clinical and Economic Review have published their cost-effectiveness analysis of remdesivir in the most recent [...]
ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available
The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. [...]
Balancing Market Access and Regulatory Requirements
Bringing a clinical product or service to market requires a careful strategy that ensures regulatory approval and value for payers. [...]
Course Available: Introduction to Health Economics and Outcomes Research
A new course is being offered by ISPOR to teach clinicians the basics of health economics and outcomes research. Participants [...]
Interview: David Kim Talks about the Tufts Cost-Effectiveness Analyzer (CEA) Registry
Assistant professor David Kim speaks with Rachel Breslau about his role as program director of the Tufts cost-effectiveness analyzer (CEA) [...]
Webinar: What Clinicians Need to Know About the Health Economic Profile of New Pharmaceuticals
Health technology assessments (HTAs) and health economic evaluations have become a pivotal fixture in market access decisions for therapeutics and [...]
ICER Releases Draft Report on Plinabulin and Trilaciclib for Chemo-induced Neutropenia
The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring [...]
Innovation and Value Initiative Welcomes 8 New Board Members
The Innovation and Value Initiative (IVI), a non-profit focused on advancing care through patient-centered value assessment, has elected 8 new [...]
Vaccines and Value Assessment – 7 Updates
Navigating the evaluation requirements from health technology assessment (HTA) agencies and national immunization technical agency groups (NITAGs) is a must [...]
Final ICER Evidence Report on Tezepelumab for Severe Asthma
A final evidence report for the clinical effectiveness and value of Tezepelumab, a treatment for severe asthma, has been released [...]
